Atlas Trials

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Clinical trial NCT06489808 · RECRUITING

Trial details

NCT number
NCT06489808
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Large B-Cell Lymphoma
Start date
2024-05-28
Primary completion
2026-12-31
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.